Malta vs Middle East, North Africa, Afghanistan & Pakistan: Immunization, HepB3
Immunization, HepB3 over time
- Malta
- Middle East, North Africa, Afghanistan & Pakistan
How they compare
Malta currently reports 97.0% against 84.4% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 12.6%.
That makes Malta's figure about 1.1 times Middle East, North Africa, Afghanistan & Pakistan's.
The two have swapped places 2 times across 22 shared years of data; in 2003 it was Malta ahead.
Malta ranks 26th and Middle East, North Africa, Afghanistan & Pakistan ranks 24th of 188 countries.
Malta has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Malta | Middle East, North Africa, Afghanistan & Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 85.6% | 72.6% | 12.9% | Malta |
| 2010s | 91.0% | 80.5% | 10.5% | Malta |
| 2020s | 98.0% | 83.4% | 14.6% | Malta |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hepb3, Malta or Middle East, North Africa, Afghanistan & Pakistan?
- Malta, at 97.0% against 84.4% in Middle East, North Africa, Afghanistan & Pakistan as of 2024.
- What is the difference in immunization, hepb3 between Malta and Middle East, North Africa, Afghanistan & Pakistan?
- 12.6%, with Malta ahead.
- How many years of comparable data are there for Malta and Middle East, North Africa, Afghanistan & Pakistan?
- 22 years are reported by both, from 2003 to 2024.
- How do Malta and Middle East, North Africa, Afghanistan & Pakistan rank globally for immunization, hepb3?
- Malta ranks 26th and Middle East, North Africa, Afghanistan & Pakistan ranks 24th of 188 countries.
- Where does this data come from?
- World Health Organization (WHO), published as Immunization, HepB3 (% of one-year-old children). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.